ZNF180 antibody - middle region (ARP35862_P050)
- Known as:
- ZNF180 (anti-) - middle region (ARP35862_P050)
- Catalog number:
- arp35862_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ZNF180 antibody - middle region (ARP35862_P050)
Related genes to: ZNF180 antibody - middle region (ARP35862_P050)
- Gene:
- ZNF180 NIH gene
- Name:
- zinc finger protein 180
- Previous symbol:
- -
- Synonyms:
- HHZ168
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-22
- Date modifiied:
- 2014-11-18
Related products to: ZNF180 antibody - middle region (ARP35862_P050)
Related articles to: ZNF180 antibody - middle region (ARP35862_P050)
- Based on our previous study, we have identified , a zinc finger protein, as a pro-tumorigenic regulator in primary melanoma and a marker for poor prognosis. Herein, we report that -regulated pathway, hence -regulome, underlies resistance towards immune checkpoint inhibitions (ICIs). - Source: PubMed
Publication date: 2025/09/18
Song Won-MinKondapuram Sree KaraniZhou XianxiaoChen Shu-HsiaAgrawal Praveen - Macrophage polarization and efferocytosis have been implicated in CHD. However, the underlying mechanisms remain elusive. This study aimed to identify CHD-associated biomarkers using transcriptomic data. - Source: PubMed
Publication date: 2024/12/05
Gao HongLi JunhuaHuang JianxinJiang Xiaojie - Most coronary artery disease (CAD) risk loci identified by genome-wide association studies (GWAS) are located in non-coding regions, hampering the interpretation of how they confer CAD risk. It is essential to integrate GWAS with molecular traits data to further explore the genetic basis of CAD. - Source: PubMed
Publication date: 2024/09/19
Li JiqingWei JiateFu PingGu Jianhua - Zinc finger protein 180 (ZNF180) is a multifunctional protein that interacts with nucleic acids and regulates various cellular processes; however, the function of ZNF180 in colorectal cancer (CRC) remains unclear. The present study investigated the role and function of ZNF180 in CRC, and aimed to reveal the underlying molecular mechanism. The results revealed that ZNF180 was downregulated in CRC tissues and was associated with a good prognosis in patients with CRC. Additionally, the expression of ZNF180 was downregulated by methylation in CRC. and experiments revealed that ZNF180 overexpression was functionally associated with the inhibition of cell proliferation and the induction of apoptosis. Mechanistically, chromatin immunoprecipitation‑PCR and luciferase assays demonstrated that ZNF180 markedly regulated the transcriptional activity of methyltransferase 14, N6‑adenosine‑methyltransferase non‑catalytic subunit (METTL14) by directly binding to and activating its promoter region. Simultaneous overexpression of ZNF180 and knockdown of METTL14 indicated that the reduction of METTL14 could suppress the effects of ZNF180 on the induction of apoptosis. Clinically, the present study observed a significant positive correlation between ZNF180 and METTL14 expression levels, and low expression of ZNF180 and METTL14 predicted a poor prognosis in CRC. Overall, these findings revealed a novel mechanism by which the ZNF180/METTL14 axis may modulate apoptosis and cell proliferation in CRC. This evidence suggests that this axis may serve as a prognostic biomarker and therapeutic target in patients with CRC. - Source: PubMed
Publication date: 2024/07/26
Xu LiangChen Xi-JieYan QianLei Xin-TaoLiu Hai-LingXu Jing-PingShang Wei-TeHuang Jing-LinChen Zhi-TingTan Xiao-LiLin Han-JieFu Xin-HuiZheng Li-ShengLan PingHuang Yan - Kawasaki disease (KD) was one of the most common primary vasculitis. IVIG resistance was associated with an increased risk of coronary artery aneurysm. Accumulating evidences demonstrated that inflammatory gene polymorphisms might play important roles in IVIG resistance, and zinc finger proteins were closely related to immune inflammation regulation, but the effect of /rs8113807 and /rs2571051 on IVIG resistance in KD patients has not been reported. - Source: PubMed
Publication date: 2022/09/02
Lu ZhaojinZheng ZepengXu YufenWang ChenluLin YuelingLin KunFu LanYanZhou HuazhongPi LeiChe DiGu Xiaoqiong